Premium
HbA1C as a marker of retrograde glycaemic control in diabetes patient with co‐existed beta‐thalassaemia: A case report and a literature review
Author(s) -
Gluvic Zoran,
Obradovic Milan,
Lackovic Milena,
Samardzic Vladimir,
Tica Jevtic Jelena,
Essack Magbubah,
Bajic Vladimir B.,
Isenovic Esma R.
Publication year - 2020
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.13073
Subject(s) - medicine , diabetes mellitus , fructosamine , surgery , insulin , quality of life (healthcare) , endocrinology , nursing
What is known and objective The HbA1C marker used in assessing diabetes control quality is not sufficient in diabetes patients with thalassaemia. Case description A male diabetic patient with thalassaemia was hospitalized due to distal neuropathic pain, right toe trophic ulcer, unacceptable five‐point glycaemic profile and recommended HbA1C value. After simultaneously initiated insulin therapy and management of ulcer by hyperbaric oxygen, the patient showed improved glycaemic control and ulcer healing, which led to the patient's discharge. What is new and conclusion In thalassaemia and haemoglobinopathies, due to discrepancies in the five‐point glycaemic profile and HbA1C values, it is necessary to measure HbA1C with a different method or to determine HbA1C and fructosamine simultaneously.